Zeiss Acquires Xradia - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Zeiss Acquires Xradia



Zeiss announced that the acquisition of U.S.-based Xradia, Inc. has been completed and Xradia is now operating under the name of Carl Zeiss X-ray Microscopy, Inc. The acquisition further strengthens the position of the ZEISS Microscopy business group, a manufacturer of light, electron, and X-ray microscopes, with solutions for research and routine inspection in materials and life sciences application fields, the company reports in a press statement.

Zeiss says reports the company will leverage its sales force to make the X-ray technology more accessible in a broader range of applications and workflows. Customers will also benefit from direct service capabilities at multiple locations globally.

http://www.zeiss.de/press/pr0039477b

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here